admin – Page 5991 – Get News Story

Hypertension Pipeline 2024 | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis,

DelveInsight, “Hypertension Pipeline Insight 2024” report provides comprehensive insights about 100+ Hypertension companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from Hypertension Pipeline Report

July 2024:- Mineralys Therapeutics Inc.- This study is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications, one of which must be a thiazide or thiazide-like diuretic. A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension.
July 2024:- Alnylam Pharmaceuticals- A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension. The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
DelveInsight’s Hypertension pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Hypertension treatment.
The leading companies working in the Hypertension Market include Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio Inc., and others.
Promising Hypertension Pipeline Therapies in the various stages of development include Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.

Request a sample and discover the recent advances in Hypertension Treatment Drugs @ Hypertension Pipeline Report

In the Hypertension pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Hypertension Overview

Hypertension is the most common primary diagnosis in the United States. It affects approximately 86 million adults (≥20 years) in the United States and is a major risk factor for stroke, myocardial infarction, vascular disease, and chronic kidney disease. Hypertension is defined as a systolic blood pressure (SBP) of 140 mm Hg or more, or a diastolic blood pressure (DBP) of 90 mm Hg or more, or taking antihypertensive medication.

Find out more about Hypertension Therapeutics Assessment @ Hypertension Preclinical and Discovery Stage Products

Hypertension Emerging Drugs Profile

Firibastat: Quantum Genomics
Baxdrostat (CIN-107): CinCor Pharma
MLS-101: Mineralys Therapeutics
Zilebesiran (ALN-AGT): Alnylam Therapeutics
IONIS-AGT-LRx: Ionis Pharmaceuticals

Hypertension Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the Hypertension therapies. The Hypertension companies which have their Hypertension drug candidates in the most advanced stage, i.e. phase III include, Reata Pharmaceuticals.

DelveInsight’s Hypertension pipeline report covers around 100+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Hypertension Pipeline Products have been categorized under various Molecule types such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Learn more about the emerging Hypertension Pipeline Therapies @ Hypertension Clinical Trials Assessment

Scope of the Hypertension Pipeline Report

Coverage- Global
Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Hypertension Companies- Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio Inc., and others.
Hypertension Pipeline Therapies- Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.

Dive deep into rich insights for new drugs for Hypertension Treatment, Visit @ Hypertension Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Hypertension: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hypertension – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Firibastat: Quantum Genomics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Baxdrostat (CIN-107): CinCor Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ID-140009: IlDong Pharmaceutical
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
CKD 331: Chong Kun Dang
Drug profiles in the detailed report…..
Inactive Products
Hypertension Key Companies
Hypertension Key Products
Hypertension- Unmet Needs
Hypertension- Market Drivers and Barriers
Hypertension- Future Perspectives and Conclusion
Hypertension Analyst Views
Hypertension Key Companies
Appendix

For further information on the Hypertension Pipeline therapeutics, reach out to Hypertension Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypertension Pipeline 2024 | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis,

Hepatocellular Carcinoma Pipeline 2024 | Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma

DelveInsight, “Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

DelveInsight’s Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
The leading companies working in the Hepatocellular Carcinoma Market include Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.
Promising Hepatocellular Carcinoma Pipeline Therapies in the various stages of development include lenvatinib, pembrolizumab (200 mg), Sorafenib, Enzalutamide, AZD9150, Nivolumab, and others.

Request a sample and discover the recent advances in Hepatocellular Carcinoma Treatment Drugs @ Hepatocellular Carcinoma Pipeline Outlook

In the Hepatocellular Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Hepatocellular Carcinoma Overview

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Cirrhosis is a significant step in viral carcinogenesis for hepatocellular carcinoma. Integration of the hepatitis B virus genome into the host genome is the primary pathogenesis for oncogenesis in HBV.

Find out more about Hepatocellular Carcinoma Treatment Landscape @ Drugs for Hepatocellular Carcinoma Treatment

Hepatocellular Carcinoma Emerging Drugs Profile

Namodenoson: Can-Fite BioPharma
SRF388: Surface Oncology
Porustobart: Harbour BioMed
Fisogatinib: CStone Pharmaceuticals
STP705: Sirnaomics

Hepatocellular Carcinoma Pipeline Therapeutics Assessment

There are approx. 90+ key Hepatocellular Carcinoma companies which are developing the therapies for Hepatocellular Carcinoma. The Hepatocellular Carcinoma companies which have their Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Can-Fite BioPharma.

DelveInsight’s Hepatocellular Carcinoma Pipeline Report covers around 95+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn more about the emerging Hepatocellular Carcinoma Pipeline Therapies @ Hepatocellular Carcinoma Clinical Trials Assessment

Scope of the Hepatocellular Carcinoma Pipeline Report

Coverage- Global
Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.
Hepatocellular Carcinoma Pipeline Therapies- lenvatinib, pembrolizumab (200 mg), Sorafenib, Enzalutamide, AZD9150, Nivolumab, and others.

Dive deep into rich insights for new drugs for Hepatocellular Carcinoma Treatment, Visit @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Hepatocellular Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Namodenoson: Can-Fite BioPharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
SRF388: Surface Oncology
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
STP705: Sirnaomics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Hepatocellular Carcinoma Key Companies
Hepatocellular Carcinoma Key Products
Hepatocellular Carcinoma- Unmet Needs
Hepatocellular Carcinoma- Market Drivers and Barriers
Hepatocellular Carcinoma- Future Perspectives and Conclusion
Hepatocellular Carcinoma Analyst Views
Hepatocellular Carcinoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatocellular Carcinoma Pipeline 2024 | Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma

Hepatitis B Virus Infection Pipeline 2024 | Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences

DelveInsight, “Hepatitis B Virus Infection Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis B Virus Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Hepatitis B Virus Infection Pipeline Report

July 2024:- GlaxoSmithKline– A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment. This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with Human Immunodeficiency Virus (HIV)/Hepatitis B Virus (HBV) co-infection.
July 2024:- Gilead Sciences– A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection. The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
DelveInsight’s Hepatitis B Virus Infection pipeline report depicts a robust space with 80+ active players working to develop 90+ pipeline therapies for Hepatitis B Virus Infection treatment.
The leading companies working in the Hepatitis B Virus Infection Market include Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
Promising Hepatitis B Virus Infection Pipeline Therapies in the various stages of development include BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.

Request a sample and discover the recent advances in Hepatitis B Virus Infection Treatment Drugs @ Hepatitis B Virus Infection Pipeline Report

In the Hepatitis B Virus Infection pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Hepatitis B Virus Infection Overview

Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B virus is transmitted via percutaneous inoculation or through mucosal exposure with infectious bodily fluids. Oral-fecal transmission is possible but considerably rare.

Find out more about Hepatitis B Virus Infection Therapeutics Assessment @ Hepatitis B Virus Infection Preclinical and Discovery Stage Products

Hepatitis B Virus Infection Emerging Drugs Profile

Bepirovirsen: GSK
VIR 2218: Vir Biotechnology
AB 729: Arbutus Biopharma
AHB-137: Ausper Biopharma

Hepatitis B Virus Infection Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the Hepatitis B Virus Infection. The Hepatitis B Virus Infection companies which have their Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. phase III include GSK.

DelveInsight’s Hepatitis B Virus Infection pipeline report covers around 90+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Hepatitis B Virus Infection Pipeline Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn more about the emerging Hepatitis B Virus Infection Pipeline Therapies @ Hepatitis B Virus Infection Clinical Trials Assessment

Scope of the Hepatitis B Virus Infection Pipeline Report

Coverage- Global
Hepatitis B Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hepatitis B Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Hepatitis B Virus Infection Companies- Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Zhejiang Palo Alto Pharmaceuticals, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, Zhimeng Biopharma, Dicerna Pharmaceuticals, Altimmune, Viravaxx, Aligos Therapeutics, GC Biopharma, Immunocore, Huahui Health, PRISM Pharma, Hepion Pharmaceuticals, Hepatera, Virion Therapeutics, and others.
Hepatitis B Virus Infection Pipeline Therapies- BRII-835, EYP001a, VIR-2218, Pegylated interferon-alfa 2a, ABI-H3733, and others.

Dive deep into rich insights for new drugs for Hepatitis B Virus Infection Treatment, Visit @ Hepatitis B Virus Infection Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Hepatitis B Virus Infection: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hepatitis B Virus Infection– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Bepirovirsen: GSK
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
VIR 2218: Vir Biotechnology
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AHB-137: Ausper Biopharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Hepatitis B Virus Infection Key Companies
Hepatitis B Virus Infection Key Products
Hepatitis B Virus Infection- Unmet Needs
Hepatitis B Virus Infection- Market Drivers and Barriers
Hepatitis B Virus Infection- Future Perspectives and Conclusion
Hepatitis B Virus Infection Analyst Views
Hepatitis B Virus Infection Key Companies
Appendix

For further information on the Hepatitis B Virus Infection Pipeline therapeutics, reach out to Hepatitis B Virus Infection Unmet Needs and Analyst Views

About Us

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hepatitis B Virus Infection Pipeline 2024 | Vir Biotechnology, Arbutus Biopharma, Nucorion Pharmaceuticals, Xian Xintong Pharmaceutical Research, Dong-A ST Co. Ltd., Gilead Sciences

Osteoarthritis Pipeline 2024 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma

DelveInsight’s, “Osteoarthritis Pipeline Insight 2024” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Osteoarthritis treatment drugs @ Osteoarthritis Pipeline Outlook

Key Takeaways from the Osteoarthritis Pipeline Report

June 2024:- New Approaches to Neuroblastoma Therapy Consortium- Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial. This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
DelveInsight’s Osteoarthritis pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis treatment.
The leading Osteoarthritis Companies working in the market include Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
Promising Osteoarthritis Therapies in the various stages of development include E1K 1,200 ㎍joint, MK0663, etoricoxib, Chondroitin 4&6 sulfate (Condrosulf), and others.

Find out more about Osteoarthritis treatment drugs @ Drugs for Osteoarthritis Treatment

Osteoarthritis Emerging Drugs Profile

Lorecivivint: Biosplice Therapeutics
CYP 004: Cynata Therapeutics
JTA-004: Bone Therapeutics
SMUP-IA-01: Medipost
TTAX03: Tissue Tech

Osteoarthritis Therapeutics Assessment

There are approx. 130+ key companies which are developing the Osteoarthritis emerging therapies. The Osteoarthritis companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics.

DelveInsight’s Osteoarthritis pipeline report covers around 130+ products under different phases of Osteoarthritis clinical trials development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Learn more about the emerging Osteoarthritis pipeline therapies @ Osteoarthritis Clinical Trials

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Oral
Intravenous
Subcutaneous

Osteoarthritis Products have been categorized under various Molecule types such as

Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy

Osteoarthritis Companies

Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.

Dive deep into rich insights for new drugs for Osteoarthritis Treatment, visit @ New Osteoarthritis Drugs

Scope of the Osteoarthritis Pipeline Report

Coverage- Global
Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
Osteoarthritis Therapies- E1K 1,200 ㎍/joint, MK0663, etoricoxib, Chondroitin 4&6 sulfate (Condrosulf), and others.

For further information on the Osteoarthritis Pipeline Therapeutics, reach out @ Osteoarthritis Treatment Drugs

Table of Content

Introduction
Executive Summary
Osteoarthritis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Osteoarthritis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Lorecivivint: Biosplice Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TTAX03: Tissue Tech
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
GLPG-0555: Gilead Sciences
Drug profiles in the detailed report…..
Preclinical Stage Products
Protego-PD: Plakous Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Osteoarthritis Key Companies
Osteoarthritis Key Products
Osteoarthritis- Unmet Needs
Osteoarthritis- Market Drivers and Barriers
Osteoarthritis- Future Perspectives and Conclusion
Osteoarthritis Analyst Views
Osteoarthritis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Osteoarthritis Pipeline 2024 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma

NK Cell Therapy Pipeline 2024 | ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Sc

DelveInsight’s, “NK Cell Therapy Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the NK Cell Therapy Pipeline. Dive into DelveInsight’s comprehensive report today! @ NK Cell Therapy Pipeline Outlook

Key Takeaways from the NK Cell Therapy Pipeline Report

June 2024:- New Approaches to Neuroblastoma Therapy Consortium- Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
DelveInsight’s NK Cell Therapy pipeline report depicts a robust space with 100+ active players working to develop 185+ pipeline therapies for NK Cell Therapy treatment.
The leading companies working in the NK Cell Therapy Market include ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.
Promising NK Cell Therapy Pipeline Therapies in the various stages of development include Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.

Stay ahead with the most recent pipeline outlook for NK Cell Therapy. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ NK Cell Therapy Treatment Drugs

NK Cell Therapy Emerging Drugs Profile

• NKTR-214: Nektar therapeutics

• Monalizumab: Innate Pharma

• Bemarituzumab: Five Prime Therapeutics

• ALT 803: ImmunityBio

• CellProtect: XNK Therapeutics

• K-NK002: Kiadis Pharma

• NK-92: ImmunityBio

• WU-NK-101: Wugen

• Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics

• ALECSAT: CytoVac

NK Cell Therapy Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Natural Killer (NK) cell therapy. The NK Cell Therapy companies which have their Natural Killer (NK) cell therapy drug candidates in the most advanced stage, i.e. Phase III include, Nektar therapeutics.

Explore groundbreaking therapies and clinical trials in the NK Cell Therapy Pipeline. Access DelveInsight’s detailed report now! @ New NK Cell Therapy Drugs

DelveInsight’s NK Cell Therapy pipeline report covers around 185+ products under different phases of clinical development like

• Late-stage products (Phase III and

• Mid-stage products (Phase II and

• Early-stage products (Phase I/II and Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

NK Cell Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Infusion

• Intradermal

• Intramuscular

• Intranasal

• Intravaginal

• Oral

• Parenteral

• Subcutaneous

• Topical.

• Molecule Type

NK Cell Therapy Pipeline Products have been categorized under various Molecule types such as

• Vaccines

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Product Type

Unveil the future of NK Cell Therapy Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ NK Cell Therapy Market Drivers and Barriers

Scope of the NK Cell Therapy Pipeline Report

• Coverage- Global

• NK Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• NK Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

• NK Cell Therapy Companies- ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, Cytovia Therapeutics, CytoImmune Therapeutics, Exacis Biotherapeutics, Novocellbio, Kuur Therapeutics (Former name: Cell Medica), Fate Therapeutics, Feldan Therapeutics, iCell Gene Therapeutics, Innate Pharma, Nkarta Therapeutics, Surface Oncology, Kiadis Pharma, Vycellix, INmune Bio, CiMass, Glycostem, Five Prime Therapeutics, Multimmune GmbH, Ambicion, Bellicum Pharmaceuticals, CARsgen therapeutics, Kuur Therapeutics, Celyad, Dragonfly Therapeutics, GamidaCell, NantKwest, Asclepius Technology Company, AffimedTherapeutics, Apceth Biopharma, Zelluna Immunotherapy, Catamaran Bio, ONK Therapeutics, Orgenesis, Navrogen, NKMAX, Nektar Therapeutics, Affimed Therapeutics, HerbiCell, Bristol-Myers Squibb, CellProtect Nordic Pharmaceuticals, CytoVac, Green Cross Corporation, NantKwest, PersonGen BioTherapeutics (Suzhou), GT Biopharma (formerly Oxis International Inc.), Nektar Therapeutics, Artiva Biotherapeutics, Senti Biosciences, oNKo-innate, Affimed Therapeutics, Agenus, Chongqing Sidemu Biotechnology, NKGen Biotech, Caribou Biosciences, Gamida-Cell, Wugen, Molmed, Century Therapeutics, KSQ Therapeutics, GT Biopharma, Shoreline Biosciences, Indapta Therapeutics, HebeCell, Sorrento therapeutics, Appia Bio, Cellatoz Therapeutics, Sanofi, Glycotype, CiMaas, CoImmune, Editas Medicine, Healios, Chimeric Therapeutics, Rubius Therapeutics, Oncternal Therapeutics, MedXCell, MiNK Therapeutics, Phio Pharmaceuticals, Biohaven Pharmaceuticals, Lava therapeutics, Allogene Therapeutics/Notch Therapeutics, Onward therapeutics, Miltenyi Biotech, and others.

• NK Cell Therapy Pipeline Therapies- Fludarabine, Cytoxan, Vax-NK/HCC, FATE-NK100, Cetuximab, Trastuzumab, ACE1702, Cyclophosphamide, and others.

Get the latest on NK Cell Therapy Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ NK Cell Therapy Companies, Key Products and Unmet Needs

Table of Content

1. Introduction

2. Executive Summary

3. Natural Killer (NK) cell therapy: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Late Stage Products (Phase III)

7. NKTR-214: Nektar therapeutics

8. Drug profiles in the detailed report…..

9. Mid Stage Products (Phase II)

10. CellProtect: XNK Therapeutics

11. Drug profiles in the detailed report…..

12. Early stage products (Phase I/II)

13. Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics

14. Drug profiles in the detailed report…..

15. Inactive Products

16. Natural Killer (NK) cell therapy Key Companies

17. Natural Killer (NK) cell therapy Key Products

18. Natural Killer (NK) cell therapy- Unmet Needs

19. Natural Killer (NK) cell therapy- Market Drivers and Barriers

20. Natural Killer (NK) cell therapy- Future Perspectives and Conclusion

21. Natural Killer (NK) cell therapy Analyst Views

22. Natural Killer (NK) cell therapy Key Companies

23. Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NK Cell Therapy Pipeline 2024 | ImmunityBio, Cantargia, CureTech, Dynavax, Cellid, Abivax, Affimed, Celularity, Glycostem Therapeutics (IPD Therapeutic), SYNIMMUNE, Celyad, Acepodia, Allife Medical Sc

Hemochromatosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and ROA, MOA by DelveInsight | Disc Medicine, Sirnaomics, Bond Biosciences, Protagonist Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hemochromatosis pipeline constitutes key companies continuously working towards developing Hemochromatosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Hemochromatosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemochromatosis Market.

The Hemochromatosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hemochromatosis Pipeline Report:

Companies across the globe are diligently working toward developing novel Hemochromatosis treatment therapies with a considerable amount of success over the years.
Hemochromatosis companies working in the treatment market are Disc Medicine, Sirnaomics, Bond Biosciences, Protagonist Therapeutics, and others, are developing therapies for the Hemochromatosis treatment

Emerging Hemochromatosis therapies in the different phases of clinical trials are- DISC a, STP 251G, BBI-001, Rusfertide, and others are expected to have a significant impact on the Hemochromatosis market in the coming years.
In July 2023, Bond Biosciences (“Bond” or “the Company”) reported favorable clinical outcomes today from its 24-person Phase 1a/b study. This randomized, double-blind, placebo-controlled, single-ascending-dose trial evaluated the safety, tolerability, and pharmacodynamic effects of BBI-001, a pioneering non-absorbed oral treatment being developed for iron overload. BBI-001 was well-tolerated with no drug-related adverse events and effectively reduced dietary iron absorption. Cory Berkland, CEO of Bond, expressed optimism about the results, noting that they confirm the mechanism and clinical activity of BBI-001 after just one dose. These findings support the company’s planned Phase II study to explore BBI-001’s potential to reduce or eliminate the need for phlebotomy in adults with Hemochromatosis (HH).

Hemochromatosis Overview

Hemochromatosis is a medical condition characterized by excessive accumulation of iron in the body, leading to potential damage to organs such as the liver, heart, and pancreas. This condition can be inherited or acquired, causing the body to absorb and store more iron than it needs. Treatment typically involves regular removal of blood (phlebotomy) to reduce iron levels and manage symptoms and complications associated with iron overload. Early diagnosis and management are crucial to prevent serious health issues associated with hemochromatosis.

Get a Free Sample PDF Report to know more about Hemochromatosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hemochromatosis-pipeline-insight

Emerging Hemochromatosis Drugs Under Different Phases of Clinical Development Include:

DISC a: Disc Medicine
STP 251G: Sirnaomics
BBI-001: Bond Biosciences
Rusfertide: Protagonist Therapeutics

Hemochromatosis Route of Administration

Hemochromatosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Hemochromatosis Molecule Type

Hemochromatosis Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Hemochromatosis Pipeline Therapeutics Assessment

Hemochromatosis Assessment by Product Type
Hemochromatosis By Stage and Product Type
Hemochromatosis Assessment by Route of Administration
Hemochromatosis By Stage and Route of Administration
Hemochromatosis Assessment by Molecule Type
Hemochromatosis by Stage and Molecule Type

DelveInsight’s Hemochromatosis Report covers around products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Hemochromatosis product details are provided in the report. Download the Hemochromatosis pipeline report to learn more about the emerging Hemochromatosis therapies

Hemochromatosis Pipeline Analysis:

The Hemochromatosis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Hemochromatosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemochromatosis Treatment.
Hemochromatosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hemochromatosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemochromatosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hemochromatosis drugs and therapies

Hemochromatosis Pipeline Market Drivers

The raising of global health awareness and Diagnosis, early illness detection and increased investment in research & development are some of the important factors that are fueling the Hemochromatosis Market.

Hemochromatosis Pipeline Market Barriers

However, No approved treatment and other factors are creating obstacles in the Hemochromatosis Market growth.

Scope of Hemochromatosis Pipeline Drug Insight

Coverage: Global
Key Hemochromatosis Companies: Disc Medicine, Sirnaomics, Bond Biosciences, Protagonist Therapeutics, and others
Key Hemochromatosis Therapies: DISC a, STP 251G, BBI-001, Rusfertide, and others
Hemochromatosis Therapeutic Assessment: Hemochromatosis current marketed and Hemochromatosis emerging therapies
Hemochromatosis Market Dynamics: Hemochromatosis market drivers and Hemochromatosis market barriers

Request for Sample PDF Report for Hemochromatosis Pipeline Assessment and clinical trials

Table of Contents

1. Hemochromatosis Report Introduction

2. Hemochromatosis Executive Summary

3. Hemochromatosis Overview

4. Hemochromatosis- Analytical Perspective In-depth Commercial Assessment

5. Hemochromatosis Pipeline Therapeutics

6. Hemochromatosis Late Stage Products (Phase II/III)

7. Hemochromatosis Mid Stage Products (Phase II)

8. Hemochromatosis Early Stage Products (Phase I)

9. Hemochromatosis Preclinical Stage Products

10. Hemochromatosis Therapeutics Assessment

11. Hemochromatosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hemochromatosis Key Companies

14. Hemochromatosis Key Products

15. Hemochromatosis Unmet Needs

16 . Hemochromatosis Market Drivers and Barriers

17. Hemochromatosis Future Perspectives and Conclusion

18. Hemochromatosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: India
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemochromatosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and ROA, MOA by DelveInsight | Disc Medicine, Sirnaomics, Bond Biosciences, Protagonist Therapeutics

BK virus infections Pipeline Insights 2024: Therapies, Clinical Trials, and Clinical Trials by DelveInsight | Orthogon Therapeutics, AiCuris, Memo Therapeutics, SymBio Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, BK virus infections pipeline constitutes 10+ key companies continuously working towards developing 10+ BK virus infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“BK virus infections Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the BK virus infections Market.

The BK virus infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the BK virus infections Pipeline Report:

Companies across the globe are diligently working toward developing novel BK virus infections treatment therapies with a considerable amount of success over the years.
BK virus infections companies working in the treatment market are Orthogon Therapeutics, AiCuris, Memo Therapeutics, SymBio Pharmaceuticals, Vera Therapeutics, AlloVir, and others, are developing therapies for the BK virus infections treatment

Emerging BK virus infections therapies in the different phases of clinical trials are- BK virus antiviral therapy, AIC 468, AntiBKV antibody, Brincidofovir, MAU868, ALVR 105, and others are expected to have a significant impact on the BK virus infections market in the coming years.
In December 2023, AlloVir announced the discontinuation of its three Phase III posoleucel studies after separate, pre-planned DSMB futility analyses determined that the studies were unlikely to meet their primary endpoints. The company will now focus on preserving capital and reviewing strategic options.
In May 2023, Memo Therapeutics AG (“MTx”), a biotechnology firm specializing in the development of top-tier therapeutic antibodies, revealed today that the U.S. Food and Drug Administration (“FDA”) has awarded Fast Track designation to AntiBKV, MTx’s primary antibody therapeutic designed to address BK polyomavirus (“BKV”) infection, frequently observed in individuals undergoing renal transplant. Having completed a phase I clinical study successfully, AntiBKV is now progressing to actively enroll patients for a crucial phase II/III clinical trial following FDA clearance.

BK virus infections Overview

BK virus (BKV) is a common virus that infects humans, usually during childhood. It belongs to the polyomavirus family and remains latent (inactive) in the body after initial infection. Most people do not experience any symptoms or health problems from BK virus infection.

Get a Free Sample PDF Report to know more about BK virus infections Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/bk-virus-bkv-infection-pipeline-insight

Emerging BK virus infections Drugs Under Different Phases of Clinical Development Include:

BK virus antiviral therapy: Orthogon Therapeutics
AIC 468: AiCuris
AntiBKV antibody: Memo Therapeutics
Brincidofovir: SymBio Pharmaceuticals
MAU868: Vera Therapeutics
ALVR 105: AlloVir

BK virus infections Route of Administration

BK virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

BK virus infections Molecule Type

BK virus infections Products have been categorized under various Molecule types, such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

BK virus infections Pipeline Therapeutics Assessment

BK virus infections Assessment by Product Type
BK virus infections By Stage and Product Type
BK virus infections Assessment by Route of Administration
BK virus infections By Stage and Route of Administration
BK virus infections Assessment by Molecule Type
BK virus infections by Stage and Molecule Type

DelveInsight’s BK virus infections Report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further BK virus infections product details are provided in the report. Download the BK virus infections pipeline report to learn more about the emerging BK virus infections therapies

Some of the key companies in the BK virus infections Therapeutics Market include:

Key companies developing therapies for BK virus infections are – AlloVir, Amplyx Pharmaceuticals, Memo therapeutics, Hybridize therapeutics, SLVaxiGenInc, and others.

BK virus infections Pipeline Analysis:

The BK virus infections pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of BK virus infections with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for BK virus infections Treatment.
BK virus infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
BK virus infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the BK virus infections market.

Download Sample PDF Report to know more about BK virus infections drugs and therapies

BK virus infections Pipeline Market Drivers

Increase in the number of patients requiring kidney transplant worldwide, technological and medical advancements, guidelines supporting early detection and prompt diagnosis are some of the important factors that are fueling the BK virus infections Market.

BK virus infections Pipeline Market Barriers

However, due to the lack of effective treatment options against BK virus infection, biology of BKPyV is not completely understood. side effects associated with the current treatment options and other factors are creating obstacles in the BK virus infections Market growth.

Scope of BK virus infections Pipeline Drug Insight

Coverage: Global
Key BK virus infections Companies: Orthogon Therapeutics, AiCuris, Memo Therapeutics, SymBio Pharmaceuticals, Vera Therapeutics, AlloVir, and others
Key BK virus infections Therapies: BK virus antiviral therapy, AIC 468, AntiBKV antibody, Brincidofovir, MAU868, ALVR 105, and others
BK virus infections Therapeutic Assessment: BK virus infections current marketed and BK virus infections emerging therapies
BK virus infections Market Dynamics: BK virus infections market drivers and BK virus infections market barriers

Request for Sample PDF Report for BK virus infections Pipeline Assessment and clinical trials

Table of Contents

1. BK virus infections Report Introduction

2. BK virus infections Executive Summary

3. BK virus infections Overview

4. BK virus infections- Analytical Perspective In-depth Commercial Assessment

5. BK virus infections Pipeline Therapeutics

6. BK virus infections Late Stage Products (Phase II/III)

7. BK virus infections Mid Stage Products (Phase II)

8. BK virus infections Early Stage Products (Phase I)

9. BK virus infections Preclinical Stage Products

10. BK virus infections Therapeutics Assessment

11. BK virus infections Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. BK virus infections Key Companies

14. BK virus infections Key Products

15. BK virus infections Unmet Needs

16 . BK virus infections Market Drivers and Barriers

17. BK virus infections Future Perspectives and Conclusion

18. BK virus infections Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: BK virus infections Pipeline Insights 2024: Therapies, Clinical Trials, and Clinical Trials by DelveInsight | Orthogon Therapeutics, AiCuris, Memo Therapeutics, SymBio Pharma

Anti-CD19 Antibody Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences, Xencor, Horizon

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Anti-CD19 Antibody pipeline constitutes key companies continuously working towards developing Anti-CD19 Antibody treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Anti-CD19 Antibody Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anti-CD19 Antibody Market.

The Anti-CD19 Antibody Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Anti-CD19 Antibody Pipeline Report:

Companies across the globe are diligently working toward developing novel Anti-CD19 Antibody treatment therapies with a considerable amount of success over the years.
Anti-CD19 Antibody companies working in the treatment market are RemeGen, Caribou Biosciences, Precision Biosciences, TG Therapeutics, Xencor, Horizon Therapeutics, Morphosys, and others, are developing therapies for the Anti-CD19 Antibody treatment

Emerging Anti-CD19 Antibody therapies in the different phases of clinical trials are- RC58, CB-010, PBCAR19B, TG-1801, Obexelimab (XmAb5871), Inebilizumab, Tafasitamab, and others are expected to have a significant impact on the Anti-CD19 Antibody market in the coming years.
In May 2024, ADC Therapeutics released topline Phase II data for its anti-CD19 antibody drug conjugate Zynlonta (loncastuximab tesirine-lpyl), showing high treatment response rates in patients with relapsed or refractory marginal zone lymphoma. The early data, from 15 evaluable patients out of 50 enrolled in the single-arm, open-label mid-stage study, revealed that 13 patients achieved complete response (CR) and one patient demonstrated partial response. All responses were maintained until the data cut-off.
In December 2023, Researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center have reported early results from a Phase I clinical trial of AT101, a novel CAR T cell therapy. This therapy, which employs a unique binding mechanism to target CD19, demonstrated a 100 percent complete response (CR) rate at higher dose levels in the trial.

Anti-CD19 Antibody Overview

An anti-CD19 antibody refers to a type of monoclonal antibody that specifically targets and binds to CD19, a protein found on the surface of B cells. CD19 is involved in the activation, proliferation, and differentiation of B cells, which play a critical role in the immune response by producing antibodies.

Get a Free Sample PDF Report to know more about Anti-CD19 Antibody Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/anti-cd19-antibody-pipeline-insight

Emerging Anti-CD19 Antibody Drugs Under Different Phases of Clinical Development Include:

RC58: RemeGen
CB-010: Caribou Biosciences
PBCAR19B: Precision Biosciences
TG-1801: TG Therapeutics
Obexelimab (XmAb5871): Xencor
Inebilizumab: Horizon Therapeutics
Tafasitamab: Morphosys

Anti-CD19 Antibody Route of Administration

Anti-CD19 Antibody pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Anti-CD19 Antibody Molecule Type

Anti-CD19 Antibody Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Anti-CD19 Antibody Pipeline Therapeutics Assessment

Anti-CD19 Antibody Assessment by Product Type
Anti-CD19 Antibody By Stage and Product Type
Anti-CD19 Antibody Assessment by Route of Administration
Anti-CD19 Antibody By Stage and Route of Administration
Anti-CD19 Antibody Assessment by Molecule Type
Anti-CD19 Antibody by Stage and Molecule Type

DelveInsight’s Anti-CD19 Antibody Report covers around products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Anti-CD19 Antibody product details are provided in the report. Download the Anti-CD19 Antibody pipeline report to learn more about the emerging Anti-CD19 Antibody therapies

Some of the key companies in the Anti-CD19 Antibody Therapeutics Market include:

Key companies developing therapies for Anti-CD19 Antibody are – TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others.

Anti-CD19 Antibody Pipeline Analysis:

The Anti-CD19 Antibody pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Anti-CD19 Antibody with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anti-CD19 Antibody Treatment.
Anti-CD19 Antibody key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Anti-CD19 Antibody Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anti-CD19 Antibody market.

Download Sample PDF Report to know more about Anti-CD19 Antibody drugs and therapies

Anti-CD19 Antibody Pipeline Market Drivers

High incidence rates of B-cell malignancies, rise in healthcare investment (by the government and private organizations) are some of the important factors that are fueling the Anti-CD19 Antibody Market.

Anti-CD19 Antibody Pipeline Market Barriers

However, side effects associated with the Treatment, high cost associated with the Treatment and other factors are creating obstacles in the Anti-CD19 Antibody Market growth.

Scope of Anti-CD19 Antibody Pipeline Drug Insight

Coverage: Global
Key Anti-CD19 Antibody Companies: RemeGen, Caribou Biosciences, Precision Biosciences, TG Therapeutics, Xencor, Horizon Therapeutics, Morphosys, and others
Key Anti-CD19 Antibody Therapies: RC58, CB-010, PBCAR19B, TG-1801, Obexelimab (XmAb5871), Inebilizumab, Tafasitamab, and others
Anti-CD19 Antibody Therapeutic Assessment: Anti-CD19 Antibody current marketed and Anti-CD19 Antibody emerging therapies
Anti-CD19 Antibody Market Dynamics: Anti-CD19 Antibody market drivers and Anti-CD19 Antibody market barriers

Request for Sample PDF Report for Anti-CD19 Antibody Pipeline Assessment and clinical trials

Table of Contents

1. Anti-CD19 Antibody Report Introduction

2. Anti-CD19 Antibody Executive Summary

3. Anti-CD19 Antibody Overview

4. Anti-CD19 Antibody- Analytical Perspective In-depth Commercial Assessment

5. Anti-CD19 Antibody Pipeline Therapeutics

6. Anti-CD19 Antibody Late Stage Products (Phase II/III)

7. Anti-CD19 Antibody Mid Stage Products (Phase II)

8. Anti-CD19 Antibody Early Stage Products (Phase I)

9. Anti-CD19 Antibody Preclinical Stage Products

10. Anti-CD19 Antibody Therapeutics Assessment

11. Anti-CD19 Antibody Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Anti-CD19 Antibody Key Companies

14. Anti-CD19 Antibody Key Products

15. Anti-CD19 Antibody Unmet Needs

16 . Anti-CD19 Antibody Market Drivers and Barriers

17. Anti-CD19 Antibody Future Perspectives and Conclusion

18. Anti-CD19 Antibody Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Anti-CD19 Antibody Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences, Xencor, Horizon

City Wide Protection Services Announces Exciting New Changes to Enhance Client Services

San Diego, CA – Jul 11, 2024 – City Wide Protection Services, a leader in the security services industry, is excited to announce several key enhancements in response to valuable client feedback. These changes are part of our ongoing commitment to deliver superior security solutions and improve client satisfaction.

Key Updates and Enhancements

1. Operational Leadership Changes

We are pleased to announce that Teresa, a familiar face to many of our clients, has been appointed as the new Operations Director. Her exceptional leadership skills and deep understanding of client needs make her the perfect fit for this role.
Tanya, who has worked closely with Teresa, will take on the role of Deputy Director of Operations. Her expertise and dedication are expected to bring fresh perspectives to our operational strategies.

2. Enhanced Training Standards

In our commitment to excellence, Randy Nuñez has joined us as the new Training Director. Randy brings a wealth of experience from his service in Army Special Operations, where he was responsible for training both military and private security personnel. His appointment is set to redefine our training programs, ensuring our security officers are prepared to handle any situation with the utmost professionalism.

3. Advanced Reporting Software

City Wide Protection Services is also set to launch a new version of our reporting software within the next 60 days. This advanced system integrates AI technology to streamline report generation, allowing our officers to focus more on their core responsibilities. Features like Geo-fence capabilities will enable real-time monitoring, enhancing accountability and service delivery.

These strategic updates reflect our proactive approach to feedback and our continuous effort to enhance the quality of our security services.

Looking Forward

We believe these changes will significantly enhance the services we provide to our valued clients, ensuring that City Wide Protection Services remains your first choice for security. We look forward to the positive impact these enhancements will have on our operations and the added value they will bring to our clients.

We appreciate the trust and support of our clients and are excited to move forward with these improvements. For more information about the new changes or any other inquiries, please contact info@cwps-ca.us

About City Wide Protection Services

City Wide Protection Services is based in San Diego, California, and offers a wide range of security services designed to provide maximum safety for both individuals and businesses. Our mission is to deliver reliable, high-quality security solutions that our clients can depend on.

Media Contact
Company Name: City Wide Protection Services
Contact Person: Media Relations
Email: Send Email
Phone: 888-205-4242
Country: United States
Website: https://www.sandiegosecurityguards.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: City Wide Protection Services Announces Exciting New Changes to Enhance Client Services

Wentworth Golf Club Recognized as One of the Top Tough Golf Courses by Golf 365

Florida’s Premier Course Ranks Sixth in National Survey

Tampa, FL – July 11, 2024 – Wentworth Golf Club, a distinguished golf course in Florida, has been honored with a prestigious ranking as one of the top tough golf courses by Golf 365. Known for its tight fairways and small greens, Wentworth has garnered a formidable reputation among golfers and experts alike, securing the sixth position in the survey.

The course, designed by the acclaimed Steve Smyers, the visionary behind Tampa’s Old Memorial, showcases his expertise and creativity. Smyers has masterfully crafted an exquisite championship golf course that gracefully winds through natural, undulating terrain teeming with wildlife. This combination of stunning scenery and strategic design makes Wentworth a true gem in the Florida golf landscape.

“We are thrilled to be recognized by Golf 365 as one of the top tough golf courses,” said Dutch Mendenhall, Owner of Wentworth Golf Club. “Our course is a testament to Steve Smyers’ brilliance and our commitment to providing a challenging yet rewarding experience for golfers of all skill levels. This accolade reflects the dedication of our team and the unique qualities that make Wentworth a standout destination for golf enthusiasts.”

Wentworth Golf Club continues to attract golfers from around the country, eager to test their skills on its demanding fairways and greens. The club’s focus on maintaining high standards of course quality and delivering exceptional service ensures a memorable experience for every visitor.

About Wentworth Golf Club:

Wentworth Golf Club is a championship golf course in Tampa, Florida, designed by renowned architect Steve Smyers. Offering a challenging yet scenic layout, Wentworth is open to the public and welcomes golfers of all skill levels. With its elegant English Manor Clubhouse and world-class amenities, Wentworth provides an unforgettable golfing experience for enthusiasts.

Media Contact
Company Name: Otter PR
Contact Person: Thomas Mustac
Email: Send Email
Address:100 E Pine St Suite 110
City: Orlando
State: Florida
Country: United States
Website: OtterPR.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wentworth Golf Club Recognized as One of the Top Tough Golf Courses by Golf 365